Eikon Therapeutics, Inc. (EIKN) stock intrinsic value fair value estimate & owner earnings analysis

Eikon Therapeutics is a clinical-stage cancer drug developer headquartered in Millbrae, California. It has no approved products and no revenue. It went public on February 6, 2026, selling 21.2 million shares at $18 for about $349 million of net proceeds, and it held about $531 million of cash and marketable securities on June 30, 2026 with no borrowings. There are about 54.2 million shares outstanding. The pipeline: EIK1001, a systemically administered TLR7/8 immune stimulant, is in a roughly 740-patient Phase 2/3 registration trial with Merck's Keytruda (pembrolizumab) in advanced melanoma, with a first interim analysis planned for the second half of 2026 to choose the dose. It is also in a Phase 2 lung cancer trial, and a roughly 750-patient Phase 2/3 lung cancer trial was at site selection. EIK1003 and EIK1004 are selective PARP1 inhibitors in Phase 1/2 trials. EIK1004 is designed to reach the brain. EIK1005, a WRN helicase inhibitor that came out of Eikon's own research platform, began Phase 1/2 dosing. EIK1001 was licensed from Seven and Eight Biotherapeutics, a Cayman Islands company with significant operations in China. The PARP1 drugs were licensed from Impact Therapeutics (Shanghai), which keeps the Greater China rights and runs trials there. Changes in U.S. policy toward Chinese biotech partners could affect these relationships. What the business earns today: nothing. After stock compensation and equipment spending, and after stripping out landlord build-out money that flowed through the lease accounts, the company used about $313 million of cash in 2024 and $331 million in 2025. In the first half of 2026 it used about $162 million, a rate of roughly $325 million a year. We measured this cash use per share on an as-converted basis, counting the preferred shares that became common at the IPO. The reported share counts were tiny before the IPO, so they would badly overstate the loss per share. How we value it: we give no value to an unapproved drug, however promising. None of the programs has randomized efficacy data, and no partner is paying for any of them, so every case gives the drugs themselves zero value. The cases differ in how much of today's cash is spent before the company learns whether that spending was worthwhile. There is a caution about the lead drug. Several late-stage attempts to improve checkpoint-inhibitor treatment of melanoma by adding a second immune drug failed their Phase 3 trials: epacadostat with Keytruda in 2018, tilsotolimod with Yervoy in 2021 and bempegaldesleukin with Opdivo in 2022. A good early signal is not enough in this setting. Bull case: the second-half 2026 melanoma interim analysis and the PARP1 combination data due in the same half come out well enough that later spending is backed by an asset outside money will pay for. Shareholders then effectively keep the cash left at the end of 2026, about $369 million. Discounted, that is about $359 million, or $6.62 per share. There is no debt to subtract. Any value the drugs have above this is upside we do not count. Base case: the 2026 readouts pick a dose and give early data but do not settle anything. Following its disclosed plan, the company spends through its stated cash runway, which runs into the second half of 2027. At about $325 million a year, roughly $44 million is left by the end of 2027, worth about $40 million today, or $0.74 per share. There is no debt. After that the company must raise new money at whatever price its data then support. Bear case: the melanoma trial fails, following the pattern above, the PARP1 and WRN programs cannot attract funding, and the company winds down in 2028 with about $44 million left. The weight is the Millbrae headquarters lease. It covers about 285,000 square feet through January 2040 and carries about $481 million of remaining rent from 2028 on, including repayment of $49.7 million in extra build-out allowances the landlord advanced. In a wind-down, U.S. bankruptcy law would likely limit the landlord's claim to about 15% of the remaining rent, roughly $72 million. The company would then owe about $28 million more than it is worth, about $26 million in today's money, or minus $0.48 per share. Shareholders would receive nothing. If the full contractual rent were owed, the shortfall would be several times larger. Other points: in its 2025 annual report the company disclosed a material weakness in how it accounts for complex lease terms. That weakness led to a restatement of its balance sheet and cash flow statement for the nine months ended September 30, 2025. Rent and the landlord allowance draws run through operating cash flow, so we did not also subtract the lease as debt except in the bear-case wind-down. About 5.5 million options (average exercise price $9.70) and 0.74 million warrants at $43.59 would be out of the money at the values above, so we left them out. What would make this wrong: randomized evidence that EIK1001 adds to Keytruda in melanoma or lung cancer, or a partner paying cash for any program. Either would give the pipeline value that no case includes today. On the other side, spending faster than about $325 million a year, as the planned lung cancer registration trial implies, would push the base case toward zero.